Below is the information acquired on BIOGEN INC., which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 31 March 2022

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

The company is primarily engaged in the development, manufacture and commercialization of therapies in the areas of oncology, neurology and immunology. It is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from the company's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. The company was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. Its headquarters is located in Cambridge, Massachusetts.The company's capabilities and capacity for protein manufacturing are world-class in quality and scale. It has expertise in protein expression in mammalian cells and process sciences capability for cell culture and downstream processing. It is one of a few biotechnology companies with three licensed and dedicated biological bulk-manufacturing facilities. These facilities include a 250,000-square-foot large-scale manufacturing (LSM) plant in Research Triangle Park (RTP), North Carolina. The LSM has 90,000 liters of bioreactor capacity and is one of the largest biologic manufacturing facilities of its kind in the world.The company also operates other licensed manufacturing facilities in RTP and Cambridge, Massachusetts and has one of the leading capacities for biologics manufacturing in the biotechnology industry. In addition, the company is building another 90,000-liter, world-class manufacturing facility located in Hillerod, Denmark. The company is one of the world's largest biotechnology companies, with an R&D budget that exceeds 750 million. The company maintains research centers of excellence in San Diego, California and Cambridge, Massachusetts.The company's products are categorized into five areas. The first area is Oncology, which include RITUXAN, ZEVALIN, Anit-CD80 mAb, Anti-CD23 mAb, M200, HSP90 Inhibitor, Anti-Cripto mAb, Anti-BR3 mAb, and Anti_IGF-1R. Under the Neurology area, products include AVONEX, TYSABRI, BG-12, RITUXAN, Daclizumab, CDP323, BIIB014/V2006, Neublastin, LINGO, and Nogo. The next area, Immunology, includes RITUXAN, FUMADERM, TYSABRI, Humanized Anti-CD20 mAb, Soluble Lymphotoxin Beta Receptro, Soluble BAFF Antagonist, Anti-CD40L, and Anti-TWEAK. The Cardiopulmonary area includes products such as Lixivaptan, ADENTRI, and Aviptadil. The last is the emerging therapeutic areas, which include long acting rFactor IX.The company has established strategic alliances with Alnylam Pharmaceuticals, Inc.; Caprion Pharmaceuticals, Inc.; UCB S.A. Ltd. (2 collaborations); Elan Corporation, plc; Genentech, Inc. (2 collaborations); MONDObiotech; NsGene A/S; PDL BioPharma, Inc. (2 collaborations); Bayer Schering Pharma; Sunesis Pharmaceuticals, Inc. (2 collaborations); Vernalis, plc; and Zenyaku Kogyo Co. Ltd.The company's direct sales force and operations are located in Canada, Spain, Portugal, Australia, and throughout Europe. The company is also active in Switzerland, Netherlands, and Japan.
  • BIOGEN INC.

  • United States of America (US)
  • Company type: Corporate
  • Parent company: N/A
  • Chief Executive Officer (CEO): Dr. Stelios B Papadopoulos
  • CEO Total remuneration: 545.858,025
  • Website: www.biogenidec.com

Financial data

Number of employees

9,610
9,100
7,400
7,800

Revenue 1

10
11
13
12

EBIT 1

3
4
7
5

EBITDA 1

4
4
7
6

1 numbers are in millions

  • RepRisk Indicator (last month):  23

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC: N/A

Standards and certifications

  • Global Compact: N/A
  • CDP (Carbon Disclosure Project): N/A
  • Modern Slavery Statement: N/A
  • Transparency Index: N/A
  • SA8000 Social Accountability: N/A
  • Integrated report: N/A
  • ISO26000: N/A
  • OECD Guidelines: N/A
  • Social Development Goals (SDGs): N/A

Global Reporting Initiative certification

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Other resources

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC: N/A
  • D. 89/391/EEC: N/A
  • D. 98/59/EC: N/A
  • D. 2000/43/EC: N/A
  • D. 2000/78/EC: N/A
  • D. 2001/23/EC: N/A
  • Council D. 2001/86/EC: N/A
  • D. 2002/14/EC: N/A
  • D. 2002/73/EC: N/A
  • Council D. 2003/72/EC: N/A
  • EP and Council D. 2005/56/EC: N/A
  • D. 2009/38/EC: N/A
  • D. 2004/25/EC: N/A
  • D. 2011/35/EU: N/A

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Reference trade unions